Nogo-A Antibodies for Progressive Multiple Sclerosis

摘要: Most of the current therapies, as well many clinical trials, for multiple sclerosis (MS) target inflammatory autoimmune processes, but less than 20% all trials investigate potential therapies chronic progressive disease stage MS. The latter is responsible steadily increasing disability in patients, and there an urgent need novel that protect nervous system tissue enhance axonal growth and/or remyelination. As outlined this review, solid pre-clinical data suggest neutralization neurite outgrowth inhibitor Nogo-A a new way to achieve both myelin repair. Several phase I studies with anti-Nogo-A antibodies have been conducted different paradigms including MS spinal cord injury. Data from injury amyotrophic lateral sclerosis (ALS) accredit good safety profile high doses administered intravenously or intrathecally. An antibody against Nogo receptor subunit, leucine rich repeat immunoglobulin-like domain-containing protein 1 (LINGO-1), was recently shown improve outcome patients acute optic neuritis II study. Nogo-A-suppressing could be drug candidates relapsing stage. In we summarize available evidence on elucidate Nogo-A-antibodies therapy